{"id":"rilpivirine-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1628504","moleculeType":"Small molecule","molecularWeight":"402.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. This ultimately inhibits the replication of the virus, reducing the viral load in the body.","oneSentence":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:23.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older"},{"name":"Prevention of HIV-1 infection in adults at high risk"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02494986","phase":"PHASE2","title":"A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":48},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT05898841","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2023-05-26","conditions":"HIV Infections, Fatty Liver Disease","enrollment":63},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT07001488","phase":"PHASE1","title":"A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV)","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2022-02-21","conditions":"Healthy","enrollment":15},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT02561936","phase":"PHASE1","title":"Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-10","conditions":"Healthy","enrollment":32},{"nctId":"NCT05349838","phase":"PHASE3","title":"Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2018-11-05","conditions":"HIV-1-infection","enrollment":140},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT03563742","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-24","conditions":"Human Immunodeficiency Virus Infections","enrollment":58},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02429791","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-14","conditions":"HIV Infections","enrollment":510},{"nctId":"NCT02422797","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-21","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT00799864","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-01","conditions":"HIV-1","enrollment":54},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04431518","phase":"PHASE4","title":"Pharmacokinetics of JULUCA in Hemodialysis","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-04-23","conditions":"HIV/AIDS, ESRD","enrollment":8},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT04371380","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-16","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT04538040","phase":"PHASE4","title":"Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine","status":"COMPLETED","sponsor":"Quest Clinical Research","startDate":"2019-12-19","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT04001803","phase":"PHASE3","title":"Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-08","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT05358756","phase":"PHASE1","title":"A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Aptorum International Limited","startDate":"2021-10-09","conditions":"Healthy Subject","enrollment":16},{"nctId":"NCT01975012","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-09","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01777997","phase":"PHASE4","title":"FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-04-25","conditions":"HIV-1 Infection","enrollment":38},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT03984838","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-06-17","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT02345252","phase":"PHASE3","title":"Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":632},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT04064632","phase":"PHASE4","title":"RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2017-02-01","conditions":"HIV Infection","enrollment":1609},{"nctId":"NCT02741557","phase":"PHASE1","title":"Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05-11","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":118},{"nctId":"NCT02707601","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-01","conditions":"HIV-1 Infection, HCV Infection","enrollment":150},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02547870","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2015-08-14","conditions":"Human Immunodeficiency Virus Type 1","enrollment":61},{"nctId":"NCT00855335","phase":"PHASE3","title":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2009-04-09","conditions":"HIV, HIV Infections, Pregnancy","enrollment":77},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT03033368","phase":"PHASE2, PHASE3","title":"Rilpivirine in Virologically Suppressed Adolescents","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2015-07","conditions":"HIV","enrollment":100},{"nctId":"NCT02530060","phase":"PHASE4","title":"A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-08","conditions":"Healthy","enrollment":8},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT02373930","phase":"PHASE1","title":"Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":63},{"nctId":"NCT00543725","phase":"PHASE3","title":"TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-06","conditions":"HIV Infections, HIV-1","enrollment":680},{"nctId":"NCT00540449","phase":"PHASE3","title":"TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-05","conditions":"HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1","enrollment":694},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01692470","phase":"","title":"A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica","startDate":"2013-06","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":""},{"nctId":"NCT02404233","phase":"PHASE4","title":"Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects","status":"UNKNOWN","sponsor":"Therapeutic Concepts","startDate":"2015-03","conditions":"HIV Positive","enrollment":30},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01715636","phase":"PHASE4","title":"Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.","status":"COMPLETED","sponsor":"Andrew Carr","startDate":"2012-12","conditions":"HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men","enrollment":100},{"nctId":"NCT00110305","phase":"PHASE2","title":"A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":368},{"nctId":"NCT01562886","phase":"PHASE1","title":"The Rilpivirine Cerebrospinal-fluid (CSF) Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-03","conditions":"HIV","enrollment":14},{"nctId":"NCT01615614","phase":"PHASE1","title":"A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT01804244","phase":"PHASE4","title":"A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-03","conditions":"Healthy","enrollment":8},{"nctId":"NCT01719614","phase":"PHASE1","title":"A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT01593046","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT01268839","phase":"PHASE1","title":"A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2010-01","conditions":"HIV","enrollment":20},{"nctId":"NCT01286740","phase":"PHASE2","title":"Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT01519128","phase":"PHASE1","title":"A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-01","conditions":"Healthy","enrollment":22},{"nctId":"NCT01205139","phase":"PHASE1","title":"TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-11","conditions":"Hepatitis C Virus","enrollment":48},{"nctId":"NCT01241773","phase":"PHASE1","title":"TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-10","conditions":"Hepatitis C Virus","enrollment":48},{"nctId":"NCT01288755","phase":"PHASE1","title":"TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-02","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00812292","phase":"PHASE1","title":"TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-01","conditions":"Pharmacokinetics, Bioavailability, HIV-1","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rilpivirine Tablets","genericName":"Rilpivirine Tablets","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rilpivirine is a medication used to treat HIV-1 infection, HIV, and HIV/AIDS. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by inhibiting the replication of the virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}